Heart Cells on a Chip

Cardiovascular diseases (CVDs) are the number one cause of deaths globally and account for 45% of deaths in Europe. Overall, heart diseases are estimated to cost the EU economy € 210 billion a year. Despite the apparent need, the number of cardiovascular drugs in the research pipeline has declined: Only four drugs targeting CVDs have been approved for use in the last decade, mostly due to the high failure rate. This is what the multidisciplinary and international consortium of three academic and six industrial (SMEs) teams united in the new Horizon 2020 project EMAPS-Cardio wants to change.